BREAKING: FDA Approves New PD Drug Funded by MJFF

On Friday, December 21, 2018, the U.S. Food and Drug Administration approved Inbrija, an inhaled levodopa powder, for the treatment of "off" episodes when Parkinson's symptoms are not well controlled with oral medication. This highly anticipated news marks another significant milestone in The Michael J. Fox Foundation's (MJFF) short history. This is the first regulatory approval of a Parkinson's treatment directly funded by the Foundation. MJFF's "de-risking" approach identifies, funds and keeps the most promising, high-risk, high-reward ideas in Parkinson's research moving forward. Read more about how we funded Inbrija in early stages of development, helping its maker drive the new treatment across the finish line and into patients' hands.     P.S. It's not too late to help MJFF speed the next breakthrough therapy from the laboratory to pharmacy shelves and Parkinson's patients. Your year-end gift today will be put to work right away to help fulfill the promise of tomorrow's new research and treatments.